CARsgen Therapeutics Holdings Ltd.

As of December 31, 2025, CARSGEN THERAPEUTICS HLDGS LTD. carries a market capitalization of 953.13M, placing it among publicly traded companies globally. Its enterprise value stands at 802.42M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CARSGEN THERAPEUTICS HLDGS LTD.'s next confirmed earnings release is scheduled for March 23, 2027.

As of December 31, 2025, CARSGEN THERAPEUTICS HLDGS LTD. has 546.16M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, CARSGEN THERAPEUTICS HLDGS LTD. maintains a current ratio of 5.73, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on September 28, 2026, CARSGEN THERAPEUTICS HLDGS LTD.'s stock has gained approximately 117.01% over the past 52 weeks.

As of December 31, 2025, CARSGEN THERAPEUTICS HLDGS LTD. holds 158.89M in cash and equivalents against 8.75M in total debt, resulting in a net debt position of -158.89M. Total book value stands at 112.02M, with working capital of 139.09M providing operational flexibility.